Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response.
neuroendocrine cancer
patient management
precision medicine
prostate cancer
targeted radionuclide therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Feb 2019
25 Feb 2019
Historique:
received:
24
01
2019
revised:
20
02
2019
accepted:
21
02
2019
entrez:
3
3
2019
pubmed:
3
3
2019
medline:
3
3
2019
Statut:
epublish
Résumé
Compared to external beam radiotherapy, targeted radionuclide therapy (TRT) allows for systemic radiation treatment of metastatic lesions. Published work on recent strategies to improve patient management and response to TRT through individualising patient treatment, modifying treatment pharmacokinetics and increasing anticancer potency are discussed in this review, with a special focus on the application of clinically evaluated radiolabelled ligands and peptides in the treatment of neuroendocrine and prostate cancers.
Identifiants
pubmed: 30823564
pii: cancers11020268
doi: 10.3390/cancers11020268
pmc: PMC6406485
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Cancer Research UK
ID : 22906
Pays : United Kingdom
Références
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
J Nucl Med. 2014 Aug;55(8):1248-52
pubmed: 24963127
Cancer Biother Radiopharm. 2014 Aug;29(6):227-37
pubmed: 25006794
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
PLoS One. 2015 Mar 16;10(3):e0116683
pubmed: 25775399
Br J Radiol. 2015 Jul;88(1051):20150042
pubmed: 25782328
Neuroendocrinology. 2016;103(5):432-9
pubmed: 26065489
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
Expert Opin Biol Ther. 2016 Aug;16(8):1035-47
pubmed: 27145158
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
Turk J Med Sci. 2016 Feb 17;46(2):409-13
pubmed: 27511504
Theranostics. 2016 Jul 18;6(11):1821-32
pubmed: 27570553
J Nucl Med. 2017 Feb;58(2):312-319
pubmed: 27587707
J Nucl Med. 2017 Feb;58(2):293-299
pubmed: 27609789
J Nucl Med. 2017 Jan;58(1):81-84
pubmed: 27660139
Oncotarget. 2017 Jan 24;8(4):7039-7049
pubmed: 27705948
Mol Imaging Biol. 2017 Jun;19(3):437-445
pubmed: 27743210
EJNMMI Res. 2016 Dec;6(1):83
pubmed: 27873240
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Clin Oncol (R Coll Radiol). 2017 May;29(5):310-315
pubmed: 28132755
Clin Oncol (R Coll Radiol). 2017 May;29(5):307-309
pubmed: 28139379
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1490-1500
pubmed: 28361189
J Nucl Med. 2017 Sep;58(9):1435-1441
pubmed: 28450554
J Nucl Med. 2017 Sep;58(9):1442-1449
pubmed: 28450562
Radiother Oncol. 2017 Sep;124(3):488-495
pubmed: 28595752
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1832-1844
pubmed: 28612079
Theranostics. 2017 Apr 27;7(7):1928-1939
pubmed: 28638478
Lancet Oncol. 2017 Jul;18(7):e414-e423
pubmed: 28677577
Theranostics. 2017 Jun 11;7(9):2350-2362
pubmed: 28744319
J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S
pubmed: 28864614
Oncotarget. 2017 Feb 25;8(33):55567-55574
pubmed: 28903443
Methods. 2017 Nov 1;130:63-71
pubmed: 28916148
J Nucl Med. 2018 Jun;59(6):909-914
pubmed: 29025985
EJNMMI Phys. 2017 Nov 21;4(1):27
pubmed: 29164483
J Nucl Med. 2018 Jun;59(6):915-921
pubmed: 29191855
EJNMMI Phys. 2017 Dec 04;4(1):28
pubmed: 29199391
Oncotarget. 2017 Oct 7;8(61):103108-103116
pubmed: 29262549
J Nucl Med. 2018 May;59(5):795-802
pubmed: 29326358
Theranostics. 2018 Jan 1;8(3):735-745
pubmed: 29344302
Nucl Med Mol Imaging. 2018 Feb;52(1):80-81
pubmed: 29391917
Mol Pharm. 2018 Mar 5;15(3):934-946
pubmed: 29400475
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169
pubmed: 29484451
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988
pubmed: 29497803
Mol Pharm. 2018 Apr 2;15(4):1457-1466
pubmed: 29502411
J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
J Nucl Med. 2018 Nov;59(11):1699-1705
pubmed: 29653971
J Vasc Interv Radiol. 2018 Aug;29(8):1094-1100
pubmed: 29754852
Nucl Med Commun. 2018 Jul;39(7):672-679
pubmed: 29790867
Oncotarget. 2018 May 15;9(37):24693-24706
pubmed: 29872498
EJNMMI Res. 2018 Jun 19;8(1):54
pubmed: 29923139
Antioxid Redox Signal. 2018 Aug 14;:null
pubmed: 29943622
Clin Cancer Res. 2018 Oct 1;24(19):4672-4679
pubmed: 29950352
J Nucl Med. 2018 Oct;59(10):1494-1499
pubmed: 30002109
Mol Imaging Biol. 2018 Jul 16;:null
pubmed: 30014345
Br J Radiol. 2018 Nov;91(1091):20170172
pubmed: 30028180
Oncotarget. 2018 Jul 6;9(52):29985-30004
pubmed: 30042828
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
J Nucl Med. 2018 Dec;59(12):1865-1868
pubmed: 30097503
EJNMMI Res. 2018 Aug 29;8(1):89
pubmed: 30159614
J Clin Endocrinol Metab. 2019 Feb 1;104(2):285-292
pubmed: 30219888
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138
pubmed: 30232539
Mol Pharm. 2018 Nov 5;15(11):5183-5191
pubmed: 30251544
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685
pubmed: 30374529
EJNMMI Res. 2018 Oct 29;8(1):96
pubmed: 30374743
J Nucl Med. 2018 Nov 15;:null
pubmed: 30442752
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
Urology. 1996 Aug;48(2):326-34
pubmed: 8753752